Milan appears in the book less as a narrated landscape than as a medical center of gravity: a place from which evidence about hepatitis C, dialysis, liver disease, and transplantation is produced and circulated. Its significance lies in this institutional role. Through Maggiore Hospital and the Milan-based nephrology community, the city is connected to the clinical description of HCV-related disease, the evaluation of long-term dialysis patients, and the broader debate over how infected patients should be treated and considered for transplantation.

Clinical and Scholarly Identity

Milan is identified as the home of Fabrizio Fabrizi and Piergiorgio Messa, whose work is associated with the Division of Nephrology and Dialysis at Maggiore Hospital, IRCCS Foundation. Their collaboration with Vivek Dixit and Paul Martin of the University of Miami places Milan within an international hepatology and nephrology network rather than an isolated local practice. The resulting chapter reviews the available evidence on HCV-related liver disease in patients undergoing long-term dialysis, making Milan one of the locations from which the clinical problem is systematically framed.

The Milan setting is therefore tied to a field in which renal failure changes the visibility of liver disease. In long-term dialysis patients, HCV-related disease is described as mostly asymptomatic, while fatigue, asthenia, and cognitive impairment may occur regardless of serologic status because dialysis patients already carry substantial clinical burdens. Biochemical clues may nevertheless appear: serum transaminase and gamma-glutamyl transpeptidase can be elevated, anti-HCV positivity has been independently associated with serum alkaline phosphatase activity in a large United States cohort, and HCV-infected patients have shown higher intact parathormone levels. Cirrhosis remains relatively infrequent among dialysis patients in the Western world, reported at approximately 1.5–2% in some international registries.

Evidence, Diagnosis, and Patient Experience

The Milan-linked clinical perspective treats diagnosis as more than the detection of an antibody. Anti-HCV antibodies identified by third-generation enzyme-linked immunosorbent assays indicate exposure, but the distinction between resolved and chronic infection depends on serum HCV RNA detected by sensitive molecular testing, with a threshold of approximately 15 IU/ml. Chronic infection requires both anti-HCV positivity and HCV RNA positivity. Active chronic infection, defined in the text as persistence of both markers for more than six months, calls for assessment of hepatic and extrahepatic effects, including cryoglobulinemia-associated vasculitis.

The evaluation of liver injury may involve biopsy or noninvasive methods. Biochemical scores such as Fibrotest, Fibrometre, Hepascore, Forns index, and Fib-4, together with elastometry by FibroScan, can reduce the need for roughly half of liver biopsies and permit yearly fibrosis follow-up in untreated patients. Yet the transplant-evaluation context preserves an important distinction between convenience and certainty: the KDIGO Workgroup judged percutaneous liver biopsy still necessary for all HCV-infected patients being considered for kidney transplantation because available noninvasive tests did not match biopsy accuracy and reliability.

Milan’s evidence also keeps the patient’s lived experience alongside laboratory measures. In a study of 165 regularly dialyzed patients, 83 of them anti-HCV positive, HCV status was independently associated with a lower mental component summary score on the SF-36, although no association with the physical component summary score was found. Depression may reflect the diagnostic label and anxiety about long-term health, or may follow fatigue and cognitive impairment; dialysis itself also increases the prevalence of depression. The clinical question consequently extends beyond viral markers and liver histology: antiviral treatment might improve quality of life even when its effect on biological measures or mortality remains uncertain.

Treatment and Its Costs

The treatment framework associated with the Milan material recognizes that therapy is recommended across stages of HCV infection but must be adapted to viral kinetics, genotype, disease impact, and the patient’s renal condition. At the acute stage, persistent HCV RNA after an average of twelve weeks indicates a twenty-four-week course of pegylated interferon, with ribavirin added for patients with HIV coinfection; detectable RNA at week four or week twelve may require extension to forty-eight weeks. In chronic infection, treatment may be considered for any patient under the EASL clinical practice guidelines, with particular emphasis on chronic fatigue, necroinflammatory hepatitis, fibrosis above stage 1 on the Metavir scale, and symptomatic extrahepatic disease such as cryoglobulinemia-associated vasculitis with renal involvement.

The therapeutic decision is constrained by toxicity. Interferon-associated adverse effects can lead to dose reduction in 35–42% of patients and treatment discontinuation in about 30%. Flu-like symptoms include fever, fatigue, headache, myalgia, and arthralgia; hematologic complications include anemia and neutropenia; neuropsychiatric effects include depression and anxiety. For patients with end-stage renal disease, these burdens are not peripheral details. They shape adherence, quality of life, eligibility for transplantation, and the practical choice between attempting viral eradication before transplantation and proceeding toward transplantation while infection remains active.

Dialysis Units and Infection Control

Although Milan is not described as the site of a single outbreak, its clinical scholarship belongs to the evidence base that redefined HCV transmission in dialysis units. Molecular studies from the mid-1990s onward used phylogenetic analysis to identify clusters of closely related HCV isolates among patients treated in the same unit. A KDIGO review of twenty such studies found that none conclusively established a specific transmission route, yet all indicated failures in infection-control procedures as the probable cause of new cases. In eighteen of the twenty studies, some or all newly infected patients had not shared a dialysis machine with the source patient, suggesting that the internal dialysis-machine circuit played, at most, a small role.

This evidence supports a prevention strategy centered on behavior and procedure rather than architectural separation. Dedicated dialysis machines for HCV-infected patients are not recommended, and isolation in a separate ward is not considered an effective substitute for strict infection-control procedures. Staff should wash their hands before and after contact with patients or station equipment, use alcohol gel when hands are not visibly contaminated, wear disposable gloves while caring for patients or touching potentially contaminated surfaces, and remove gloves when leaving the station. Single-use items should be discarded after one patient; reusable items should be disinfected or dedicated to one patient; and station surfaces should be cleaned after each session, with stronger disinfection for visible contamination. Audits of infection-control practice should be integrated into unit performance reviews because broad agreement about hygiene does not guarantee that precautions are actually applied.

Waiting Lists and Transplant Policy

The Milan-associated literature also enters the institutional management of HCV-positive patients awaiting kidney transplantation. Patients who have not previously been tested should undergo anti-HCV screening with confirmation by nucleic acid testing in low-prevalence regions, or direct nucleic acid testing in high-prevalence settings. Those with positive HCV RNA should be placed on hold status and referred to a hepatologist for evaluation and possible treatment. Patients who achieved a sustained virologic response before transplantation should undergo at least annual nucleic acid testing to confirm that the response persists; relapse likewise requires hold status and consideration of retreatment. Patients who remain viremic require annual assessment to ensure that liver disease has not progressed.

The waiting list is not a neutral interval. In one cited group of patients who remained on the list and underwent repeat liver biopsy, 8 of 13, or 62%, showed worsening liver histology. After transplantation, only 7 of 31, or 23%, showed interval worsening on follow-up biopsy. The contrast gives transplantation a double meaning: it is an organ-replacement procedure, but it can also alter the trajectory of HCV-related liver disease. At the same time, treatment before transplantation may be prolonged, expensive, poorly tolerated, or unsuccessful, and patients receiving interferon after transplantation face the risk of renal-graft dysfunction. Milan’s role in the book is thus inseparable from a difficult clinical balance between viral clearance, waiting-list time, treatment toxicity, liver progression, and graft preservation.